enGene Holdings Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

—

Shrs. gr., 5y

26.45%

Rev. gr., 5y

Revenues

Net income

CFO

Dividend

Dec 01, 20140.14 USD/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.

URL

https://engene.com/

IPO date

Dec 10, 2021

Employees

Domiciled in

Incorporated in

Valuation

No data to show